MX2024013146A - Moduladores de atenuador de linfocitos b y t (btla) y método de uso de los mismos - Google Patents

Moduladores de atenuador de linfocitos b y t (btla) y método de uso de los mismos

Info

Publication number
MX2024013146A
MX2024013146A MX2024013146A MX2024013146A MX2024013146A MX 2024013146 A MX2024013146 A MX 2024013146A MX 2024013146 A MX2024013146 A MX 2024013146A MX 2024013146 A MX2024013146 A MX 2024013146A MX 2024013146 A MX2024013146 A MX 2024013146A
Authority
MX
Mexico
Prior art keywords
btla
modulators
binding agent
lymphocyte attenuator
disease
Prior art date
Application number
MX2024013146A
Other languages
English (en)
Spanish (es)
Inventor
Martin Edward Dahl
Stephen Parmley
Paul Lizzul
Eric Hare
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of MX2024013146A publication Critical patent/MX2024013146A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024013146A 2022-04-27 2024-10-24 Moduladores de atenuador de linfocitos b y t (btla) y método de uso de los mismos MX2024013146A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263335623P 2022-04-27 2022-04-27
PCT/US2023/066258 WO2023212611A1 (en) 2022-04-27 2023-04-26 B and t lymphocyte attenuator (btla) modulators and method of using same

Publications (1)

Publication Number Publication Date
MX2024013146A true MX2024013146A (es) 2025-01-09

Family

ID=86558778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013146A MX2024013146A (es) 2022-04-27 2024-10-24 Moduladores de atenuador de linfocitos b y t (btla) y método de uso de los mismos

Country Status (9)

Country Link
US (1) US20250282872A1 (enExample)
EP (1) EP4514850A1 (enExample)
JP (1) JP2025515337A (enExample)
KR (1) KR20250007603A (enExample)
AU (1) AU2023259623A1 (enExample)
CA (1) CA3256715A1 (enExample)
IL (1) IL316496A (enExample)
MX (1) MX2024013146A (enExample)
WO (1) WO2023212611A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004633A (es) * 2020-10-23 2023-05-12 Anaptysbio Inc Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
CA2769473A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
MX2023004633A (es) * 2020-10-23 2023-05-12 Anaptysbio Inc Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.

Also Published As

Publication number Publication date
WO2023212611A1 (en) 2023-11-02
JP2025515337A (ja) 2025-05-14
IL316496A (en) 2024-12-01
CA3256715A1 (en) 2023-11-02
US20250282872A1 (en) 2025-09-11
KR20250007603A (ko) 2025-01-14
EP4514850A1 (en) 2025-03-05
AU2023259623A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
BR112021024507A2 (pt) Agonista de pd-1 e método de uso do mesmo
CL2020002042A1 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
WO2022087441A3 (en) B and t lymphocyte attenuator (btla) modulators and method of using same
MX2020011828A (es) Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
CO2022004743A2 (es) Anticuerpos dirigidos a flt3 y uso de los mismos
EA202090812A1 (ru) Новые биспецифические полипептидные комплексы
CO2021016907A2 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
EP4560368A3 (en) Systems, devices, and methods for improved optical waveguide transmission and alignment
MX2022000456A (es) Anticuerpos biespecificos simetricos tetravalentes.
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
CL2025000313A1 (es) Anticuerpos para btla
CR20220330A (es) Anticuerpos anti-ly6g6d y métodos de uso.
AR128031A1 (es) Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
BR112021026890A2 (pt) Composições de anticorpo para interromper biofilmes
AR117565A1 (es) Agentes de unión a c3 y método de uso de los mismos
AR111752A1 (es) Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos
MX2024012309A (es) Anticuerpos cd200r diseñados por ingeniería y usos de estos
MX2020011588A (es) Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
MX2023008172A (es) Anticuerpo biespecifico de forma heterodimerica similar a la estructura del anticuerpo natural anti-pd-l1/anti-4-1bb y preparacion del mismo.
CL2025002112A1 (es) Anticuerpo anti-npr1; método de producción; y su uso.
CR20250226A (es) Anticuerpo anti-trem2 y usos del mismo
CO2026002703A2 (es) Agentes de unión al antígeno cd3 estabilizados y métodos de uso de estos
CO2025012855A2 (es) Sistemas orientados a psma y ca9
MX2023003929A (es) Anticuerpos cd1a y su uso.